一分钟看懂
这是一项关于结直肠癌的II 期研究，登记的药物或干预包括Short-course radiotherapy；Capecitabine；Oxaliplatin；TME surgery；PD -1/PD-L1 monoclonal antibody；Watch & Wait strategy，当前状态为尚未开始招募。登记地点显示中国武汉有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Short-course radiotherapy；Capecitabine；Oxaliplatin；TME surgery；PD -1/PD-L1 monoclonal antibody；Watch & Wait strategy · II 期
登记条件中文摘要
年龄范围：18岁至75岁
登记的基本范围为不限性别，年龄18岁至75岁；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出3项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 武汉
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- 1. Patients or their family members agree to participate in the study and sign the informed consent form;
- 2. Age 18-75 years, male or female;
- 3. Histologically confirmed Locally Advanced rectal adenocarcinoma;
- 4. inferior margin ≤ 10 cm from the anal verge;
- 5. ECOG performance status score is 0-1;
- 6. Untreated with anti-tumor therapy for rectal cancer, including radiotherapy, chemotherapy, surgery, etc;
- 7. There was no operative contraindication;
- 8. Laboratory tests were required to meet the following requirements: white blood cell (WBC) ≥ 4×109/L; Absolute neutrophil count (ANC) ≥ 1.5×109/L; Platelet count ≥ 100×109/L; Hemoglobin ≥90 g/L; Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN); Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; Serum creatinine ≤1.5 times the upper limit of normal value or creatinine clearance rate ≥50 mL/min; International normalized ratio (INR) ≤ 1.5 × ULN; Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07847229；登记信息更新于 2026-10-06；本站同步于 2026-10-08。